This study is testing a new medicine called KRT-232 for people with a type of blood cancer called Chronic Myeloid Leukemia (CML). CML can happen when the body makes too many white blood cells. Some patients may not respond to a common treatment called a Tyrosine Kinase Inhibitor (TKI). This study aims to check if KRT-232 can help those patients. It's an open-label study, which means that both doctors and patients know they are getting the study medicine.

To be in the study, you need to be 18 years or older, have a certain type of CML, and be in good overall health. You cannot join if you have specific mutations or have tried similar medicines before. The study will look at how safe KRT-232 is and how well it works.

• Study includes multiple phases and arms, meaning different groups of treatment and testing.
• Participants must be adults who have not responded well or cannot tolerate TKI medicines.
• Regular health checks will be required to ensure safety and effectiveness of treatment.